Health Care & Life Sciences » Pharmaceuticals | Pacira Pharmaceuticals Inc.

Pacira Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
63,909.00
13,716.00
1,856.00
37,949.00
42,611.00
471
Depreciation, Depletion & Amortization
5,747.00
10,035.00
11,475.00
12,919.00
13,833.00
13,165
Other Funds
19,361.00
29,606.00
38,009.00
36,204.00
49,137.00
47,033
Funds from Operations
38,801.00
25,925.00
51,340.00
11,174.00
20,359.00
59,727
Changes in Working Capital
3,981.00
514.00
24,552.00
22,279.00
2,574.00
10,857
Net Operating Cash Flow
42,782.00
26,439.00
26,788.00
33,453.00
17,785.00
48,870
Capital Expenditures
12,794.00
21,889.00
40,295.00
24,709.00
19,266.00
Purchase/Sale of Investments
28,735.00
84,017.00
28,158.00
21,188.00
196,039.00
Net Investing Cash Flow
43,560.00
119,339.00
19,256.00
61,754.00
223,765.00
Issuance/Reduction of Debt, Net
84,875.00
970.00
1,743.00
4.00
215,522.00
Net Financing Cash Flow
88,731.00
117,905.00
10,423.00
7,261.00
224,162.00
Net Change in Cash
2,389.00
25,005.00
17,955.00
21,040.00
18,182.00
Free Cash Flow
55,576.00
4,550.00
13,507.00
8,744.00
1,481.00
Change in Capital Stock
3,856.00
118,875.00
12,166.00
7,265.00
8,640.00
Other Uses
2,031.00
13,433.00
7,119.00
15,857.00
8,460.00

About Pacira Pharmaceuticals

View Profile
Address
5 Sylvan Way
Parsippany New Jersey 07054
United States
Employees -
Website http://www.pacira.com
Updated 07/08/2019
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.